Skip to main content
Back
AXGN logo

AxoGen, Inc.

Data quality: 100%
AXGN
NASDAQ Healthcare Medical - Devices
$33.28
▲ $0.67 (2.05%)
Mkt Cap: 1.73B
Day Range
$32.77 $33.59
52-Week Range
$9.22 $36.00
Volume
791,517
50D / 200D Avg
$32.62 / $22.22
Prev Close
$32.61

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -110.0 0.3
P/B 13.4 3.0
ROE % -13.5 3.7
Net Margin % -7.0 3.8
Rev Growth 5Y % 15.3 10.0
D/E 0.2 0.2

Analyst Price Target

Hold
$38.38 +15.3%
Low: $34.00 High: $41.00
Forward P/E
64.87
Forward EPS
$0.51
EPS Growth (est.)
+0.0%
Est. Revenue
266.19M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.70
$1.68 – $1.72
 531.90M 1
FY2029 $1.31
$1.29 – $1.32
 425.03M 1
FY2028 $0.99
$0.98 – $1.00
 365.85M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-24 $0.09 $0.07 -21.2%
2025-10-29 $0.09 $0.12 +33.3%
2025-08-05 $0.06 $0.12 +100.0%
2025-05-08 -$0.01 -$0.02 -100.0%
2025-02-25 $0.04 $0.08 +100.0%
2024-11-07 $0.01 $0.07 +1066.7%
2024-08-08 -$0.05 $0.05 +200.0%
2024-05-02 -$0.10 -$0.06 +40.0%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Jan 27, 2010 Feb 12, 2010 $1.00 22.22%
Feb 23, 2005 — $0.06 2.61%
Jul 10, 1992 — $0.04 0.50%

Key Takeaways

Revenue grew 15.32% annually over 5 years — strong growth
Debt/Equity of 0.15 — conservative balance sheet
Negative free cash flow of -2.93M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4.89%
Capital efficient — spends only 1.66% of revenue on capex

Growth

Revenue Growth (5Y)
15.32%
Revenue (1Y)20.21%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-13.49%
ROIC-3.98%
Net Margin-6.97%
Op. Margin-3.49%

Safety

Debt / Equity
0.15
Current Ratio5.11
Interest Coverage-1.02

Valuation

P/E Ratio
-109.99
Forward P/E61.89
P/B Ratio13.40
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20.21% Revenue Growth (3Y) 19.01%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 15.32% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 225.21M Net Income (TTM) -15.70M
ROE -13.49% ROA -7.08%
Gross Margin 74.31% Operating Margin -3.49%
Net Margin -6.97% Free Cash Flow (TTM) -2.93M
ROIC -3.98% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.15 Current Ratio 5.11
Interest Coverage -1.02
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -109.99 Forward P/E 61.89
P/B Ratio 13.40 P/S Ratio 7.67
PEG Ratio -2.01 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 6.49 Fwd Earnings Yield 1.62%
FCF Yield -0.17%
Market Cap 1.73B Enterprise Value 1.71B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 225.21M 187.34M 159.01M 138.58M 127.36M
Net Income -15.70M -9.96M -21.72M -28.95M -26.99M
EPS (Diluted) -0.34 -0.23 -0.51 -0.69 -0.65
Gross Profit 167.35M 141.98M 121.87M 108.81M 104.43M
Operating Income -7.85M -3.29M -21.46M -29.71M -25.42M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 221.69M 203.73M 196.83M 195.39M 208.02M
Total Liabilities 92.84M 99.82M 101.16M 94.39M 95.47M
Shareholders' Equity 128.85M 103.91M 95.67M 101.00M 112.55M
Total Debt 19.24M 68.69M 69.29M 67.43M 67.45M
Cash & Equivalents 35.55M 27.55M 31.02M 15.28M 32.76M
Current Assets 120.42M 99.22M 88.00M 98.08M 127.05M
Current Liabilities 23.56M 30.61M 30.43M 23.75M 24.29M